Citations

Clear

6 citation(s) found for "Mu, Yunmei".

Increased mTORC2 activity in naive T cells from older adults impairs asymmetric cell division 2309021
Roy, Abhishek , Mu, Yunmei, Yang, Qiankun, Own, Maryam , Weyand, Cornelia, Goronzy, Jörg, Sturmlechner, Ines , Jain, Abhinav , Weyand, Cornelia M.

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.1489 Get It

Abstract Introduction The ability of the adaptive immune system to have memory of previous pathogen encounters is the basis for vaccination as one of the most successful medical interventions. With increasing age, the ability to develop protective immunity after vaccination declines. Differentiation into T memory cells is at least in part determined during the early cell divisions after activation when cells undergo assymmetric cell division (ACD). Fate decisions depend on the uneven distribution of signaling molecules and transcription factors with accumulation of mTORC1 activity biasing for an effector and TCF1 for a memory state. We explored whether ACD of naïve CD4 T cells is impaired in older adults. Methods We used human primary cells from young and older adults. Human naive CD4 T cells were isolated and cultured in RPMI, 10% FBS and antibiotics on plates coated with anti-CD3 Ab, anti-CD28 Ab and huICAM1 for 3 days. We used transfection by electroporation to modify gene expression. Read out systems included confocal microscopy, flow cytometry and lysosome function assays. Results were compared by t-test with values of p < 0.05 considered significant. Results Naive CD4 T cell responses from older adults is characterized by increased activation of the AKT-mTORC1 pathway and reduced ACD of mTORC1 activity. Increased RICTOR expression resulting in increased mTORC2 activity in naive CD4 T cells from older individuals accounted for the activation of the AKT-mTORC1 pathway. AKT inhibition or silencing of RICTOR restores ACD of mTORC1 activity as well as of TCF1. Conversely, ACD was also improved through inducing WNT signaling by GSK3β inhibition irrespective of RICTOR expression. Conclusion Our data show that increased RICTOR expression in naïve T cells from older adults at least in part accounts for defective memory cell generation. Silencing of RICTOR or downstream AKT inhibition can enforce both mTORC1 ACD and TCF1 ACD suggesting that mTORC2 is a promising target to improve vaccine responses. Funding Source n/a Topic Categories Lymphocyte Differentiation and Peripheral Maintenance (LYM)
Antigen-specific T H 17 cells offset the age-related decline in durable T cell immunity
Sturmlechner, Ines , Jain, Abhinav , Jiang, Jingjing , Okuyama, Hirohisa , Mu, Yunmei, Own, Maryam , Weyand, Cornelia M. , Goronzy, Jörg J. , Jain, Abhinav , Goronzy, Jorg , Sturmlechner, Ines

Mayo Clinic

Science Advances | February 6, 2026 | Volume: 12 | Issue: 6 | Pages: No page available

10.1126/sciadv.aea7131 | PMID 41650263 Get It

Older adults are susceptible to infections in part due to waning of immune memory. To uncover mechanisms of a long-lasting immune memory, we contrasted varicella zoster virus antigen–specific memory T cell responses in adults vaccinated at young (<20 years) or older age (>50 years) with a live-attenuated vaccine conferring durable protection only when given at young age or with an adjuvanted component vaccine eliciting long-lasting immunity in older adults. Unlike VZV-specific CD4 + T cells, CD8 + T cells exhibited profound age-sensitive changes including memory subset shifts, reduced T cell receptor diversity, and loss of stem-like features. Vaccination of older adults with the adjuvanted vaccine did not restore CD8 + defects but selectively enhanced T helper 17 (T H 17) CD4 + T cells and prevented their conversion into regulatory T cells, likely through lipid metabolic regulation. Thus, durable vaccine efficacy with aging relies on antigen-specific T H 17 cells that compensate for CD8 + T cell defects.
Antigen-specific Th17 T cells offset the age-related decline in durable T cell immunity
Sturmlechner, Ines , Jain, Abhinav , Jiang, Jingjing , Okuyama, Hirohisa , Mu, Yunmei, Own, Maryam , Weyand, Cornelia M. , Goronzy, Jörg J. , Jain, Abhinav , Goronzy, Jorg , Sturmlechner, Ines

Mayo Clinic

No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.05.658069 | PMID 40502174 Get It

ABSTRACT Older adults are susceptible to infections, in part due to waning of immune memory. To determine mechanisms that determine long-lasting versus short-term immunity, we examined varicella zoster virus (VZV) vaccination as a model system. We contrasted VZV antigen-specific T cells several years after vaccination in adults who had been vaccinated at young (<20 years) or older age (>50 years) with a live-attenuated vaccine that confers durable protection only when given at young age, or with an adjuvanted VZV component vaccine that elicits effective, long-lasting immunity in older adults. CD8 + T cells were highly sensitive to age-related changes showing T cell subset shifts, loss in TCR diversity and reduced stem-like features while gaining NK-like signatures without evidence for cellular senescence or exhaustion. VZV-specific CD4 + T cells were largely resilient to age and maintained phenotypic and TCR diversity. Immunization of older adults with the adjuvanted VZV vaccine did not reverse age-associated defects in CD8 + T cells. Instead, it selectively improved the functionality of VZV-specific Th17 CD4 + T cells and prevented their acquisition of Treg features, likely as consequence of lipid metabolic pathways. Collectively, our data indicate that effective vaccination in older adults is supported by the generation of a durable, antigen-specific CD4 + Th17 population that resists mis-differentiation into Tregs and that compensates for age-related defects in CD8 + T cells. One sentence summary Aging primarily impairs the CD8 + T cell VZV vaccine response, while effective VZV vaccination in older adults induces antigen-specific Th17 CD4 + T cells to compensate for aging defects.
Improvement of multilineage hematopoiesis in hematopoietic stem cell-transferred c-kit mutant NOG-EXL humanized mice
Ito, Ryoji , Mu, Yunmei , Ito, Shuko, Emi-Sugie, Maiko, Mochizuki, Misa, Goto, Motohito , Ogura, Tomoyuki , Niwa, Akira , Nakahata, Tatsutoshi , Ito, Mamoru , Ohno, Yusuke , Ka, Yuyo , Kawai, Kenji , Takahashi, Riichi

Mayo Clinic

No container title available | September 5, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3267519/v1 Get It

Abstract Human hematopoietic stem cell (HSC)-transferred humanized mice are valuable for exploring human hematology and immunology. However, sufficient recapitulation of human hematopoiesis in mice requires large quantities of enriched human CD34+ HSCs and total body irradiation for adequate engraftment. Recently, we generated a NOG mouse strain with a point mutation in the c-kit tyrosine kinase domain (W41 mutant; NOGW mice). Herein, we first examined the potential of NOGW mice for reconstituting human hematopoietic cells. Irradiated NOGW mice exhibited a high engraftment level of human CD45+ cells in peripheral blood, even on transferring 5,000–10,000 CD34+ HSCs. The efficient engraftment of human CD45+ cells was also observed in non-irradiated NOGW mice transferred with 20,000–40,000 HSCs. The bone marrow (BM) of NOGW mice exhibited significantly more engrafted human HSCs or progenitor cells (CD34+CD38− or CD34+CD38+ cells) than the BM of NOG mice. Furthermore, we generated a human cytokine (interleukin-3 and granulocyte-macrophage colony-stimulating factor) transgenic NOG-W41 (NOGW-EXL) mouse to achieve multilineage reconstitution with sufficient engraftment of human hematopoietic cells. Non-irradiated NOGW-EXL mice showed significantly higher engraftment levels of human CD45+ and myeloid lineage cells, particularly granulocytes and platelets/megakaryocytes, than non-irradiated NOGW or irradiated NOG-EXL mice after human CD34+ cell transplantation. Serial BM transplantation experiments revealed that NOGW mice exhibited the highest potential for long-term HSC compared with other strains. Consequently, c-kit mutant NOGW-EXL humanized mice represent an advanced model for HSC-transferred humanized mice and hold promise for widespread application owing to their high versatility.
IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression
Cao, Wenqiang , Mu, Yunmei, Okuyama, Hirohisa , Li, Lingjie , Qiu, Jingtao , Weyand, Cornelia M. , Goronzy, Jörg J. , Goronzy, Jorg , Cao, Wenqiang , Fang, Fengqin

Mayo Clinic

JCI Insight | June 21, 2022 | Volume: 7 | Issue: 12 | Pages: No page available

10.1172/jci.insight.157509 | PMID 35730568 Get It

The ectonucleotidase CD39 functions as a checkpoint in purinergic signaling on effector T cells. By depleting eATP and initiating the generation of adenosine, it impairs memory cell development and contributes to T cell exhaustion, thereby causing defective tumor immunity and deficient T cell responses in older adults who have increased CD39 expression. Tuning enzymatic activity of CD39 and targeting the transcriptional regulation of ENTPD1 can be used to modulate purinergic signaling. Here, we describe that STAT6 phosphorylation downstream of IL-4 signaling represses CD39 expression on activated T cells by inducing a transcription factor network including GATA3, GFI1, and YY1. GATA3 suppresses ENTPD1 transcription through prevention of RUNX3 recruitment to the ENTPD1 promoter. Conversely, pharmacological STAT6 inhibition decreases T cell effector functions via increased CD39 expression, resulting in the defective signaling of P2X receptors by ATP and stimulation of A2A receptors by adenosine. Our studies suggest that inhibiting the STAT6 pathway to increase CD39 expression has the potential to treat autoimmune disease while stimulation of the pathway could improve T cell immunity.
Critical role for Syk in responses to vascular injury
André, Patrick, Morooka, Toshifumi, Sim, Derek , Abe, Keith , Lowell, Clifford A. , Nanda, Nisha, Delaney, Suzanne M., Siu, Gail, Yan, Yibing, Hollenbach, Stan, Gao, Huiyun, Wang, Yunmei, Nakajima, Kohsuke, Parikh, Sahil A. , Shi, Can , Owen, Whyte G., Sinha, Uma, Simon, Daniel I. , Pandey, Anjali , Phillips, David R.

Mayo Clinic

Blood | September 1, 2011 | Volume: 118 | Issue: 18 | Pages: 5000-5010

10.1182/blood-2011-06-360743 | PMID 21881044 Get It

AbstractAlthough current antiplatelet therapies provide potent antithrombotic effects, their efficacy is limited by a heightened risk of bleeding and failure to affect vascular remodeling after injury. New lines of research suggest that thrombosis and hemorrhage may be uncoupled at the interface of pathways controlling thrombosis and inflammation. Here, as one remarkable example, studies using a novel and highly selective pharmacologic inhibitor of the spleen tyrosine kinase Syk [PRT060318; 2-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)pyrimidine-5-carboxamide] coupled with genetic experiments, demonstrate that Syk inhibition ameliorates both the acute and chronic responses to vascular injury without affecting hemostasis. Specifically, lack of Syk (murine radiation chimeras) attenuated shear-induced thrombus formation ex vivo, and PRT060318 strongly inhibited arterial thrombosis in vivo in multiple animal species while having minimal impact on bleeding. Furthermore, leukocyte-platelet–dependent responses to vascular injury, including inflammatory cell recruitment and neointima formation, were markedly inhibited by PRT060318. Thus, Syk controls acute and long-term responses to arterial vascular injury. The therapeutic potential of Syk may be exemplary of a new class of antiatherothrombotic agents that target the interface between thrombosis and inflammation.